Rachel H. Fong

Rachel H. Fong

Auto-generated profile, based on publicly available information

Rachel H. Fong

Integral Molecular, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Cell
Verified
Journal Article
Closed access
AKArthur S. Kim
Arthur S. Kim
NKNatasha M. Kafai
Natasha M. Kafai
EWEmma S. Winkler
Emma S. Winkler
TGTheron C. Gilliland
Theron C. Gilliland
ECEmily L. Cottle
Emily L. Cottle
MDMichael Diamond
Michael Diamond

22 February 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Jarrod J. MousaJarrod J. Mousa
Jarrod J. Mousa
EBElad Binshtein
Elad Binshtein
SHStacey Human
Stacey Human
RFRachel H. Fong
Rachel H. Fong
GAGabriela Alvarado
Gabriela Alvarado
JCJames E. Crowe
James E. Crowe
Respiratory syncytial virus (RSV) is a major human pathogen that infects the majority of children by two years of age. The RSV fusion (F) protein is a primary target of human antibodies, and it has several antigenic regions capable of inducing neutralizing antibodies. Antigenic site IV is preserved in both the pre-fusion and post-fusion conformations of RSV F. Antibodies to antigenic site IV have been described that bind and neutralize both RSV and human metapneumovirus (hMPV). To explore the diversity of binding modes at antigenic site IV, we generated a panel of four new human monoclonal antibodies (mAbs) and competition-binding suggested the mAbs bind at antigenic site IV. Mutagenesis experiments revealed that binding and neutralization of two mAbs (3M3 and 6F18) depended on arginine (R) residue R429. We discovered two R429-independent mAbs (17E10 and 2N6) at this site that neutralized an RSV R429A mutant strain, and one of these mAbs (17E10) neutralized both RSV and hMPV. To determine the mechanism of cross-reactivity, we performed competition-binding, recombinant protein mutagenesis, peptide binding, and electron microscopy experiments. It was determined that the human cross-reactive mAb 17E10 binds to RSV F with a binding pose similar to 101F, which may be indicative of cross-reactivity with hMPV F. The data presented provide new concepts in RSV immune recognition and vaccine design, as we describe the novel idea that binding pose may influence mAb cross-reactivity between RSV and hMPV. Characterization of the site IV epitope bound by human antibodies may inform the design of a pan-Pneumovirus vaccine. Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are major causes of viral bronchiolitis and pneumonia in infants and children. A licensed vaccine is not currently available for either virus, therefore, the characterization of the human antibody response to these viruses is of the utmost importance. In this study, we identified four new human monoclonal antibodies that target antigenic site IV of the RSV F protein. Using a combination of alanine mutagenesis, protein binding experiments, and electron microscopy, we defined several modes of antibody recognition at antigenic site IV, including a mAb with a unique binding angle that neutralizes RSV and hMPV. The data presented provide new concepts that will aid in the development of vaccines for RSV and hMPV.

28 September 2021 in Virology
Verified
Journal Article
Open access
ACAmanda Calvert
Amanda Calvert
SBSusan L. Bennett
Susan L. Bennett
AHAnn R. Hunt
Ann R. Hunt
RFRachel H. Fong
Rachel H. Fong
BDBenjamin J. Doranz
Benjamin J. Doranz
CBCarol D. Blair
Carol D. Blair
Eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV) and Venezuelan equine encephalitis virus (VEEV) can cause fatal encephalitis in humans and equids. Some MAbs to the E1 glycoprotein are known to be cross-reactive, weakly neutralizing in vitro but can protect from disease in animal models. We investigated the mechanism of neutralization of VEEV infection by the broadly cross-reactive E1-specific MAb 1A4B-6. 1A4B-6 protected 3-week-old Swiss Webster mice prophylactically from lethal VEEV challenge. Likewise, 1A4B-6 inhibited virus growth in vitro at a pre-attachment step after virions were incubated at 37 °C and inhibited virus-mediated cell fusion. Amino acid residue N100 in the fusion loop of E1 protein was identified as critical for binding. The potential to elicit broadly cross-reactive MAbs with limited virus neutralizing activity in vitro but that can inhibit virus entry and protect animals from infection merits further exploration for vaccine and therapeutic developmental research.